HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

briakinumab

anti-IL-12/23 monoclonal antibody
Also Known As:
A-796874.0; ABT-874; ABT-874 antibody, human; BSF 415977; BSF-415977; J-695; J695; LU 415977; LU-415977; WAY-165772
Networked: 38 relevant articles (10 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Gordon, Kenneth B: 5 articles (02/2012 - 02/2008)
2. Langley, Richard G: 5 articles (02/2012 - 02/2008)
3. Khanna, Reena: 3 articles (12/2019 - 05/2015)
4. MacDonald, John K: 3 articles (12/2019 - 05/2015)
5. Williams, D A: 3 articles (06/2014 - 09/2011)
6. Kimball, Alexa B: 3 articles (08/2011 - 02/2008)
7. Menter, Alan: 3 articles (08/2011 - 02/2008)
8. Nguyen, Tran M: 2 articles (12/2019 - 11/2016)
9. Timmer, Antje: 2 articles (11/2016 - 05/2015)
10. Sandborn, William J: 2 articles (06/2015 - 01/2004)

Related Diseases

1. Psoriasis (Pustulosis Palmaris et Plantaris)
02/01/2008 - "The percentage of patients achieving a 75% reduction in the Psoriasis Area and Severity Index at week 12 was statistically significantly greater in all of the ABT-874 treatment groups than in the placebo group (200 mg once, 63% [19 of 30]; 100 mg every other week for 12 weeks, 93% [28 of 30]; 200 mg weekly for 4 weeks, 90% [27 of 30]; 200 mg every other week for 12 weeks, 93% [28 of 30]; 200 mg weekly for 12 weeks, 90% [27 of 30]; placebo, 3% [1 of 30]; P < .001). "
08/01/2009 - "Although limited by small sample sizes, length of follow-up, and a lack of direct comparisons with other psoriasis treatments, initial data regarding the safety and efficacy of briakinumab for the treatment of psoriasis is promising. "
06/01/2014 - "Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study."
02/01/2012 - "In one phase II and four phase III studies (including two 52-week trials), the Psoriasis Area and Severity Index (PASI)-75 score at weeks 12 and 52 was achieved by at least 80.6% and 66.2% (p < 0.001) of patients receiving more than one dose of briakinumab every 4 weeks, respectively, with high proportions of patients achieving PASI-90 and PASI-100 scores (at least 55.4% and 28.8%, respectively; p < 0.001). "
02/01/2011 - "ABT-874, an anti-interleukin-12 and -23 antibody, was previously shown to be significantly more effective compared with placebo during a 12-week phase II study of psoriasis. "
2. Crohn Disease (Crohn's Disease)
3. Ulcerative Colitis
4. Infections
5. Stroke (Strokes)

Related Drugs and Biologics

1. Interleukin-12 (IL 12)
2. Ustekinumab (CNTO 1275)
3. Monoclonal Antibodies
4. Interleukin-23 (Interleukin 23)
5. Etanercept (Enbrel)
6. Antibodies
7. Interleukins
8. risankizumab
9. Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
10. Pharmaceutical Preparations

Related Therapies and Procedures

1. Therapeutics
2. Retreatment
3. Biological Therapy